Q-omics provides the consensus-scored STRADA profile across patient tissues and cancer cell-line models. STRADA expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, STRADA is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, STRADA RNA expression shows 20,948 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where STRADA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STRADA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STRADA survival associations across molecular data types. STRADA RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STRADA RNA expression–survival associations across cancer types. High STRADA expression shows unfavorable associations in KIRC, KICH and LGG, but favorable associations in UCS, PAAD and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for STRADA RNA expression.
This table summarizes STRADA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for STRADA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STRADA shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, BLCA, CHOL and STAD. The HNSC box plot shows higher STRADA RNA expression in tumor versus normal tissue (log2 FC = +0.538, t-test p < 0.001).
This table shows molecular features associated with STRADA in patient tissues and cancer cell lines. In patient samples, STRADA shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, STRADA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
